MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3899/jrheum.2022-1320

Медицинская библиотека · The Journal of rheumatology · 2023

Abatacept as Monotherapy and in Combination With Methotrexate in Patients With Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials.

Ruperto Nicolino, Lovell Daniel J, Berman Alberto, Anton Jordi, Viola Diego O, Lauwerys Bernard, Rama Maria E, Bohnsack John, Breedt Johannes, Fischbach Michel, Lutz Thomas, Minden Kirsten, Ally Mahmood, Rubio-Pérez Nadina, Gervais Elisabeth, Van Zyl Riana, Wong Robert, Askelson Margarita, Martini Alberto, Brunner Hermine I, Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO)

Клиническое исследование III фазыСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

To describe the efficacy and safety data of children with polyarticular-course juvenile idiopathic arthritis (pcJIA) treated with abatacept (ABA) + methotrexate (MTX) or ABA monotherapy when prior MTX use was either ineffective or not tolerated.

METHODS

Posthoc analysis of 2 phase III trials of subcutaneous (SC) and intravenous (IV) ABA over 2 years in patients with pcJIA (aged 2-17 years). Patients were stratified by treatment with ABA + MTX or ABA monotherapy and further by prior biologic use. Efficacy outcomes included JIA-American College of Rheumatology (JIA-ACR) responses, Juvenile Arthritis Disease Activity Score in 27 joints using C-reactive protein (JADAS27-CRP), and safety. Descriptive pharmacokinetic analyses were also performed.

RESULTS

Efficacy responses (JIA-ACR and JADAS27-CRP) were similar between patients receiving ABA + MTX (n = 310) or ABA monotherapy (n = 99) and persisted over 2 years. Clinical response rates were similar in biologic-naïve patients and prior biologic users; this was independent of MTX use. Across both studies, ABA + MTX and ABA monotherapy displayed similar safety profiles. Pharmacokinetic results revealed similar minimum steady-state trough ABA concentrations between studies. Further, baseline MTX did not influence ABA clearance and was not a significant predictor of JIA-ACR responses.

CONCLUSION

ABA monotherapy (SC and IV) was effective and well tolerated in children with pcJIA when prior MTX use was ineffective or not tolerated. Treatment effects of ABA appear to be independent of MTX coadministration. Consequently, ABA monotherapy can be considered for those with prior biologic therapy if MTX use is inappropriate. (ClinicalTrials.gov: NCT01844518 and NCT00095173).

Для цитирования: Ruperto Nicolino, Lovell Daniel J, Berman Alberto, Anton Jordi, Viola Diego O, Lauwerys Bernard, Rama Maria E, Bohnsack John, Breedt Johannes, Fischbach Michel, Lutz Thomas, Minden Kirsten, Ally Mahmood, Rubio-Pérez Nadina, Gervais Elisabeth, Van Zyl Riana, Wong Robert, Askelson Margarita, Martini Alberto, Brunner Hermine I, Pediatric Rheumatology Collaborative Study Group (PRCSG) and the Paediatric Rheumatology International Trials Organisation (PRINTO). Abatacept as Monotherapy and in Combination With Methotrexate in Patients With Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials.. The Journal of rheumatology. 2023. DOI: 10.3899/jrheum.2022-1320.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.